Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal‐Cell Carcinoma

[1]  P. Hegde,et al.  Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Fossati,et al.  Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma , 2016, World Journal of Urology.

[3]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[4]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[5]  S. Signoretti,et al.  Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma , 2015, Cancer.

[6]  T. Ho,et al.  PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation , 2015, Cancer Immunology Research.

[7]  T. Choueiri,et al.  Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2015, Clinical genitourinary cancer.

[8]  R. Paridaens,et al.  Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. , 2014, Clinical genitourinary cancer.

[9]  E. Porfiri,et al.  Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib. , 2014, Clinical genitourinary cancer.

[10]  R. Figlin,et al.  Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis. , 2013, Urologic oncology.

[11]  J. Long,et al.  [Sarcomatoid renal cell carcinoma]. , 2013, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[12]  Dae-Ho Lee,et al.  Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component , 2013, Journal of Cancer Research and Clinical Oncology.

[13]  G. Gibney,et al.  c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Manola,et al.  A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 , 2012, Medical Oncology.

[15]  L. Schwartz,et al.  Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease , 2011, American journal of clinical oncology.

[16]  A. Ravaud,et al.  Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma , 2011, Oncology.

[17]  C. Porta,et al.  TREATMENT OF METASTATIC RENAL CARCINOMA PATIENTS WITH THE COMBINATION OF GEMCITABINE, CAPECITABINE AND BEVACIZUMAB AT A TERTIARY CANCER CENTRE , 2011, BJU international.

[18]  E. Jonasch,et al.  Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre , 2011, BJU international.

[19]  M. Bader,et al.  Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell Carcinoma: a prospective evaluation , 2010, European journal of medical research.

[20]  Karl J. Dykema,et al.  Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study , 2010, Molecular Cancer Therapeutics.

[21]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[23]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[24]  P. Russo,et al.  Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. , 2007, The Journal of urology.

[25]  E. Small,et al.  A phase II study of gemcitabine and capecitabine in metastatic renal cancer , 2006, Cancer.

[26]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Liang Cheng,et al.  Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation , 2005, Cancer.

[28]  N. Bissada,et al.  Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. , 2005, American journal of clinical oncology.

[29]  M. Gore,et al.  Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma , 2004, British Journal of Cancer.

[30]  M. Milowsky,et al.  Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.

[31]  J. Cheville,et al.  Sarcomatoid Renal Cell Carcinoma: An Examination of Underlying Histologic Subtype and an Analysis of Associations With Patient Outcome , 2004, The American journal of surgical pathology.

[32]  C. Ohyama,et al.  Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma , 2003, International Journal of Clinical Oncology.

[33]  S. Horvath,et al.  Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors , 2003, Urological Research.

[34]  S. Culine,et al.  Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. , 2002, The Journal of urology.

[35]  P. D. Dal Cin,et al.  Chromosome changes in sarcomatoid renal carcinomas are different from those in renal cell carcinomas. , 2002, Cancer genetics and cytogenetics.

[36]  H. Moch,et al.  Sarcomatoid Differentiation in Renal Cell Carcinoma: A Study of 101 Cases , 2001, The American journal of surgical pathology.

[37]  P. Bhargava,et al.  Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[39]  B. Rini,et al.  Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[41]  R. Figlin,et al.  Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Ishikawa,et al.  Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. , 1995, Cancer research.

[43]  C. Logothetis,et al.  Sarcomatoid renal cell carcinoma. A treatable entity , 1987, Cancer.

[44]  J. Ro,et al.  Sarcomatoid renal cell carcinoma: Clinicopathologic. A study of 42 cases , 1987, Cancer.

[45]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[46]  W. Linehan,et al.  Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. , 2012, The oncologist.

[47]  M. Gordon.  A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents , 2009 .

[48]  M. Gordon.  Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy , 2009 .

[49]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[50]  P. Pisters,et al.  Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. , 2002, The Journal of urology.

[51]  B. Delahunt.  Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies. , 1999, Pathology.

[52]  S. Culine,et al.  Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy? , 1995, European urology.